SELLAS Life Sciences Group, Inc. Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31)
SELLAS Life Sciences Group, Inc. (SLS) reported Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31) of $0 for the 12-month period ending 2015-12-31, per its 10-K/A filed 2016-04-15.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfSecuritiesNet · last filed 2016-04-15
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for the quarter ending 2013-12-31 was $2.52M.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for the quarter ending 2013-09-30 was $814.00K.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for fiscal 2015 was $0.00.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for fiscal 2013 was $3.91M.
- SELLAS Life Sciences Group, Inc. gain (loss) on sale of securities, net (deprecated 2018-01-31) for fiscal 2011 was $0.00.
| Period end | Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31) 3 month | Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31) 6 month | Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31) 9 month | Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31) 12 month | Gain (Loss) on Sale of Securities, Net (Deprecated 2018-01-31) 126 month |
|---|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K/A · filed 2016-04-15 | ||||
| 2014-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-04-15 | $0.00 derived: sum of 2 quarters · filed 2016-04-15 | $0.00 10-K/A · filed 2016-04-15 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $0.00 10-Q · filed 2014-11-05 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | ||||
| 2013-12-31 | $2.52M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-04-15 | $3.33M derived: sum of 2 quarters · filed 2016-04-15 | $3.91M 10-K/A · filed 2016-04-15 | ||
| 2013-09-30 | $814.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $1.39M 10-Q · filed 2014-11-05 | |||
| 2013-06-30 | $578.00K 10-Q · filed 2014-08-11 | $578.00K 10-Q · filed 2013-08-09 | |||
| 2012-12-31 | $0.00 derived: 8-K 12 month − 10-Q/A 9 month · filed 2015-12-04 | $0.00 derived: sum of 2 quarters · filed 2015-12-04 | $0.00 8-K · filed 2015-12-04 | ||
| 2012-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2013-11-07 | $0.00 10-Q/A · filed 2013-11-07 | |||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-09 | ||||
| 2011-12-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |